Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
BACKGROUND: Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. METHODS: Surv...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868017/ https://www.ncbi.nlm.nih.gov/pubmed/33549037 http://dx.doi.org/10.1186/s12885-021-07855-z |
_version_ | 1783648386783641600 |
---|---|
author | Jiao, Dechuang Zhang, Jingyang Zhu, Jiujun Guo, Xuhui Yang, Yue Xiao, Hui Liu, Zhenzhen |
author_facet | Jiao, Dechuang Zhang, Jingyang Zhu, Jiujun Guo, Xuhui Yang, Yue Xiao, Hui Liu, Zhenzhen |
author_sort | Jiao, Dechuang |
collection | PubMed |
description | BACKGROUND: Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. METHODS: Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. RESULTS: Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). CONCLUSIONS: Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients. |
format | Online Article Text |
id | pubmed-7868017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78680172021-02-08 Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis Jiao, Dechuang Zhang, Jingyang Zhu, Jiujun Guo, Xuhui Yang, Yue Xiao, Hui Liu, Zhenzhen BMC Cancer Research Article BACKGROUND: Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. METHODS: Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. RESULTS: Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). CONCLUSIONS: Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients. BioMed Central 2021-02-06 /pmc/articles/PMC7868017/ /pubmed/33549037 http://dx.doi.org/10.1186/s12885-021-07855-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Jiao, Dechuang Zhang, Jingyang Zhu, Jiujun Guo, Xuhui Yang, Yue Xiao, Hui Liu, Zhenzhen Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title | Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_full | Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_fullStr | Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_full_unstemmed | Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_short | Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis |
title_sort | comparison of survival in non-metastatic inflammatory and other t4 breast cancers: a seer population-based analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868017/ https://www.ncbi.nlm.nih.gov/pubmed/33549037 http://dx.doi.org/10.1186/s12885-021-07855-z |
work_keys_str_mv | AT jiaodechuang comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT zhangjingyang comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT zhujiujun comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT guoxuhui comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT yangyue comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT xiaohui comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis AT liuzhenzhen comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis |